Krystal Biotech (KRYS) PT Raised to $35 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Krystal Biotech (KRYS) PT Raised to $50 at Chardan Capital Markets
October 16, 2018 3:59 PM EDTChardan Capital Markets analyst Gbola Amusa raised the price target on Krystal Biotech (NASDAQ: KRYS) to $50.00 (from $35.00) while maintaining a Buy rating.
Amusa raised the target on positive early data from Krystal's phase I/II trial (NCT03536143) of KB103 in dystrophic epidermolysis bullosa... More
Krystal Biotech (KRYS) PT Raised to $35.50 at H.C. Wainwright
October 15, 2018 11:47 AM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Krystal Biotech (NASDAQ: KRYS) to $35.50 (from $32.00) while maintaining a Buy rating after the company announced interim results from its ongoing Phase 1/2 study with KB103, delivered topically, in two patients affected by Recessive Dystrophic Epidermic... More
Krystal Biotech (KRYS) Reports Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103
October 15, 2018 7:46 AM EDTKrystal Biotech, Inc. (NASDAQ: KRYS) today announced positive interim results from its ongoing placebo-controlled Phase 1/2 clinical trial of KB103.
GEM Study Status updateTwo adult Recessive Dystrophic Epidermolysis Bullosa (RDEB), NC1[+] patients aged 35 and 28 years old have completed treatment with topical KB103 to date. The patients were re-dosed during the study. In each patient, two wounds with... More
